SLC5A2 and diabetic kidney disease: The anti‐diabetic SGLT2 inhibitors (SGLT2i) not only prove to be effective in reducing blood glucose levels but they also show decent efficacy in slowing down the progression of diabetic kidney disease.[155, 156, 157, 158, 159, 160] A very recent study by Maegawa and colleagues showed that increased ketone body production might be one of the mechanisms how SGLT2i have a protective role in diabetic kidney disease.